Controlled Crossover Study of AIONX Antimicrobial Surface for the Prevention of Healthcare-associated Infections

Aionx

Status and phase: Unknown; Phase 2

Conditions: Healthcare Associated Infection

Treatments: Device: Antimicrobial Surface

Study type: Interventional

Funder types: Industry

Identifiers

NCT03189043

7371

Details and patient eligibility

About

This is a controlled open label efficacy study of Aionx antimicrobial surface for the prevention of healthcare-associated infections.

Full description

The study is an open label controlled efficacy trial of Aionx patented antimicrobial surface for the prevention of healthcare-associated infections (HAIs). It will take place at Penn State Hershey. Half of the single occupancy rooms of the 5th and 7th floor will be assigned to contain the antimicrobial surface at five locations: bed rails, overbed table, door handles, counter, and arm rests of bedside chair. The remaining rooms will serve as controls. Data on HAIs will be gathered for all the patients admitted to the rooms during the duration of the study. After 45 days the rooms will be flipped so that test rooms become controls and control rooms become test rooms. The duration of the study will be for a minimum of 90 days.

Enrollment: 10,000 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Admission to a single occupancy room in a participating floor at Hershey Medical Center

Exclusion criteria

• Refusal to participate in the study.

Trial design

Primary purpose: Prevention

Allocation: Non-Randomized

Interventional model: Crossover Assignment

Masking: None (Open label)

---

10,000 participants in 2 patient groups

Test

Experimental group

Description:

Use of antimicrobial surface

Treatment:

Device: Antimicrobial Surface

Control

No Intervention group

Description:

No antimicrobial surface